DK0710121T3 - Fremgangsmåde til behandling af dissemineret sklerose - Google Patents
Fremgangsmåde til behandling af dissemineret skleroseInfo
- Publication number
- DK0710121T3 DK0710121T3 DK93917954T DK93917954T DK0710121T3 DK 0710121 T3 DK0710121 T3 DK 0710121T3 DK 93917954 T DK93917954 T DK 93917954T DK 93917954 T DK93917954 T DK 93917954T DK 0710121 T3 DK0710121 T3 DK 0710121T3
- Authority
- DK
- Denmark
- Prior art keywords
- necrosis factor
- tumour necrosis
- disseminated sclerosis
- treating disseminated
- factor receptor
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 102000018594 Tumour necrosis factor Human genes 0.000 abstract 3
- 108050007852 Tumour necrosis factor Proteins 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010054094 Tumour necrosis Diseases 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preliminary Treatment Of Fibers (AREA)
- Transplanting Machines (AREA)
- Spinning Or Twisting Of Yarns (AREA)
- Treatment Of Fiber Materials (AREA)
- Peptides Or Proteins (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB1993/001614 WO1995003827A1 (en) | 1993-07-30 | 1993-07-30 | Method for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0710121T3 true DK0710121T3 (da) | 2001-02-05 |
Family
ID=10729416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK93917954T DK0710121T3 (da) | 1993-07-30 | 1993-07-30 | Fremgangsmåde til behandling af dissemineret sklerose |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5958409A (da) |
| EP (2) | EP1004312A1 (da) |
| JP (1) | JPH09509646A (da) |
| AT (1) | ATE196849T1 (da) |
| AU (1) | AU4719093A (da) |
| DE (1) | DE69329558T2 (da) |
| DK (1) | DK0710121T3 (da) |
| ES (1) | ES2153384T3 (da) |
| GR (1) | GR3035196T3 (da) |
| PT (1) | PT710121E (da) |
| WO (1) | WO1995003827A1 (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| US7070783B1 (en) | 1995-05-09 | 2006-07-04 | The Mathilda And Terence Kennedy Institute Of Rheumatology | Small molecular weight TNF receptor multimeric molecule |
| US7012060B1 (en) | 1995-07-14 | 2006-03-14 | Applied Research Systems Ars Holding N.V. | TNF receptor and steroid hormone in a combined therapy |
| DK0839046T3 (da) | 1995-07-14 | 2002-02-18 | Applied Research Systems | TNF-receptor og steroidhormon i en kombinationsterapi |
| US7608262B2 (en) * | 1996-02-16 | 2009-10-27 | The Kennedy Institute Of Rheumatology | Methods of preventing or treating thrombosis with tumor necrosis factor antagonists |
| TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| IL127851A0 (en) * | 1998-12-30 | 1999-10-28 | Applied Research Systems | Inhibition of TNF activity |
| US8119127B2 (en) * | 1999-02-24 | 2012-02-21 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| US6982089B2 (en) * | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| USRE45976E1 (en) * | 1999-02-24 | 2016-04-19 | Tact Ip, Llc | Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally |
| AU6929100A (en) * | 1999-08-23 | 2001-03-19 | Biocrystal Limited | Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis |
| CN1684708A (zh) * | 2001-05-30 | 2005-10-19 | 基因技术股份有限公司 | 抗ngf抗体用于治疗各种疾病 |
| US20050175585A1 (en) * | 2001-06-11 | 2005-08-11 | Transition Therapeutics Inc. | Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases |
| EP1401484A1 (en) * | 2001-06-11 | 2004-03-31 | Transition Therapeutics Inc. | Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases |
| JP4417113B2 (ja) * | 2002-02-20 | 2010-02-17 | エミスフェアー・テクノロジーズ・インク | Ｇｌｐ−１分子の投与方法 |
| US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| US7101978B2 (en) | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
| US7435799B2 (en) | 2004-01-08 | 2008-10-14 | Applied Molecular Evolution | TNF-α binding molecules |
| US8236306B2 (en) * | 2004-12-18 | 2012-08-07 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
| CA2635445A1 (en) * | 2006-02-22 | 2007-08-30 | University Of Zurich | Methods for treating autoimmune or demyelinating diseases |
| UA116648C2 (uk) | 2013-03-14 | 2018-04-25 | Алкермес Фарма Айерленд Лімітед | Фумарати як проліки та їх застосування при лікуванні різних захворювань |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| US9604922B2 (en) | 2014-02-24 | 2017-03-28 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL98078A0 (en) * | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
| JP3443119B2 (ja) * | 1989-08-07 | 2003-09-02 | ペプテック リミテッド | 腫瘍壊死因子結合リガンド |
| DE10399023I2 (de) * | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| DE4202665A1 (de) * | 1992-01-28 | 1993-07-29 | Schering Ag | Prostacyclin- und carbacyclinderivate als mittel zur behandlung von multipler sklerose |
-
1993
- 1993-07-30 EP EP99203261A patent/EP1004312A1/en not_active Ceased
- 1993-07-30 EP EP93917954A patent/EP0710121B1/en not_active Expired - Lifetime
- 1993-07-30 DK DK93917954T patent/DK0710121T3/da active
- 1993-07-30 JP JP7505635A patent/JPH09509646A/ja not_active Ceased
- 1993-07-30 PT PT93917954T patent/PT710121E/pt unknown
- 1993-07-30 DE DE69329558T patent/DE69329558T2/de not_active Expired - Lifetime
- 1993-07-30 ES ES93917954T patent/ES2153384T3/es not_active Expired - Lifetime
- 1993-07-30 AT AT93917954T patent/ATE196849T1/de active
- 1993-07-30 WO PCT/GB1993/001614 patent/WO1995003827A1/en not_active Ceased
- 1993-07-30 AU AU47190/93A patent/AU4719093A/en not_active Abandoned
- 1993-07-30 US US08/586,917 patent/US5958409A/en not_active Expired - Lifetime
-
2001
- 2001-01-10 GR GR20010400014T patent/GR3035196T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GR3035196T3 (en) | 2001-04-30 |
| DE69329558D1 (de) | 2000-11-16 |
| PT710121E (pt) | 2001-04-30 |
| EP1004312A1 (en) | 2000-05-31 |
| EP0710121A1 (en) | 1996-05-08 |
| US5958409A (en) | 1999-09-28 |
| ATE196849T1 (de) | 2000-10-15 |
| WO1995003827A1 (en) | 1995-02-09 |
| ES2153384T3 (es) | 2001-03-01 |
| JPH09509646A (ja) | 1997-09-30 |
| EP0710121B1 (en) | 2000-10-11 |
| AU4719093A (en) | 1995-02-28 |
| DE69329558T2 (de) | 2001-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0710121T3 (da) | Fremgangsmåde til behandling af dissemineret sklerose | |
| DK0603305T3 (da) | Anvendelse af et thymosin til behandling af hepatitis C | |
| IT1261949B (it) | Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo. | |
| NO932905L (no) | Fremgangsmaate for fremstilling av hydrokarbon-brennstoffer | |
| NO912794D0 (no) | Boresystem og fremgangsmaate for styring av retningen paa boringer i grunnformasjoner. | |
| IT1177389B (it) | Composizioni analgesiche ed anti-infiammatorie migliorate, comprendente xantine e metodi di utilizzare le stesse | |
| MY131298A (en) | 5-heteroyl indole derivatives | |
| SE8401942L (sv) | Anti-tumorsubstans och forfarande for framstellning av densamma | |
| NO850058L (no) | Modifisert kolofoniumharpiks, og fremgangsmaate til fremstilling og anvendelse derav | |
| ATE155345T1 (de) | Gegengift immunsera | |
| NO853342L (no) | Fremgangsmaate og anordning for framstilling av hulplater og andre byggeelementer, saerlig av betong. | |
| FI915126L (fi) | Mineraloljemellandestillat med foerbaettrade flytegenskaper i koeld. | |
| DK101197A (da) | Medikament til behandling af thrombocytopenia | |
| DK0588873T3 (da) | Behandling af levercancer | |
| FR2700162B1 (fr) | Composite liant hydraulique-granulat lignocellulosique, sa fabrication et ses applications. | |
| DE3878529D1 (de) | Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen. | |
| TW350898B (en) | Sliding member and manufacture thereof | |
| FI930342A7 (fi) | Immuunijärjestelmää ja hermostoa sääteleviä pentapeptidejä | |
| FI915244A7 (fi) | Biometallurginen prosessi, jossa suoritetaan mineraaliyhdisteiden biohapetus | |
| DK0766655T3 (da) | Fremgangsmåde til fremstilling af et afretningslag | |
| DE58901521D1 (de) | Tragschichtfertiger. | |
| RO86650B1 (ro) | Preparat farmaceutic pentru tratarea dermatozelor | |
| SE9003704D0 (sv) | New selenophen derivatives, a preparation process of the samme and therapeutical compositions containing them | |
| UA10734A (uk) | Спосіб лікуваhhя виразкової хвороби 12-палої кишки | |
| DK152713B (da) | Belaegningsmasse til gader, veje, parkeringspladse r, med mere og fremgangsmaade til fremstilling af belaegningsmassen. |